The MTHFR 677C→T polymorphism and risk of prostate cancer: results from the CAPS study

[1]  T. Guthrie,et al.  Prostate cancer. , 2020, American family physician.

[2]  P. Stattin,et al.  Polymorphisms of methylenetetrahydrofolate reductase and the risk of prostate cancer: a nested case–control study , 2006, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[3]  J. Chang-Claude,et al.  Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study , 2006, British Journal of Cancer.

[4]  Mark Lucock,et al.  Folic acid — vitamin and panacea or genetic time bomb? , 2005, Nature Reviews Genetics.

[5]  Antony V. Cox,et al.  DNA Methylation Profiling of the Human Major Histocompatibility Complex: A Pilot Study for the Human Epigenome Project , 2004, PLoS biology.

[6]  J. Schlesselman,et al.  Polymorphisms in the methylenetetrahydrofolate reductase gene and prostate cancer risk. , 2004, International journal of oncology.

[7]  M. Spitz,et al.  Polymorphisms of folate metabolic genes and susceptibility to bladder cancer: a case-control study. , 2004, Carcinogenesis.

[8]  Pär Stattin,et al.  H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer. , 2004, Journal of the National Cancer Institute.

[9]  J. Witte,et al.  Relationship between methylenetetrahydrofolate reductase C677T and A1298C genotypes and haplotypes and prostate cancer risk and aggressiveness. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[10]  S. Vollset,et al.  Geographical and ethnic variation of the 677C>T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wide , 2003, Journal of medical genetics.

[11]  J. Boer,et al.  A common variant of the methylenetetrahydrofolate reductase gene (1p36) is associated with an increased risk of cancer. , 2003, Cancer research.

[12]  S. Ebrahim,et al.  'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? , 2003, International journal of epidemiology.

[13]  P. Stattin,et al.  Non‐systematic screening for prostate cancer in SwedenSurvey from the National Prostate Cancer Registry , 2003, Scandinavian journal of urology and nephrology.

[14]  S. Cnattingius,et al.  Plasma folate levels and risk of spontaneous abortion. , 2002, JAMA.

[15]  J H Eckfeldt,et al.  The 1298A-->C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. , 2001, Atherosclerosis.

[16]  M. Fenech.  The role of folic acid and Vitamin B12 in genomic stability of human cells. , 2001, Mutation research.

[17]  S. Vollset,et al.  Biological and clinical implications of the MTHFR C677T polymorphism. , 2001, Trends in pharmacological sciences.

[18]  P. Simpson,et al.  Statistical methods in cancer research , 2001, Journal of surgical oncology.

[19]  W. Schulz,et al.  Methyl group metabolism gene polymorphisms and susceptibility to prostatic carcinoma , 2000, The Prostate.

[20]  L. Holmberg,et al.  Three common CFTR mutations should be included in a neonatal screening programme for cystic fibrosis in Sweden , 1999, Clinical genetics.

[21]  Paul D. Allison,et al.  Logistic regression using sas®: theory and application , 1999 .

[22]  A. Cassoni.  Tnm Classification of Malignant Tumours , 1987 .

[23]  R. Matthews,et al.  A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase , 1995, Nature Genetics.

[24]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[25]  N. Breslow,et al.  Statistical methods in cancer research: volume 1- The analysis of case-control studies , 1980 .